InvestSMART

Neuren Pharmaceuticals Limited (ASX: NEU) - Announcements

Current share price for NEU : $22.740 0.24 (1.04%)+

ASX company news and announcements for Neuren Pharmaceuticals Limited (NEU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Neuren Pharmaceuticals Limited (NEU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Neuren Pharmaceuticals Limited (NEU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Neuren Pharmaceuticals Limited (NEU)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
$2,883 Acadia enters DAYBUE STIX distribution agreement in Japan 17 Nov 2026 9:52AM $22.980 $22.740 fallen by 1.04%
$2,883 Final Director's Interest Notice - P. Davies 12 Nov 2026 10:27AM $23.930 $22.740 fallen by 4.97%
$2,883 Initial Director's Interest Notice - Zita Peach 12 Nov 2026 10:26AM $23.930 $22.740 fallen by 4.97%
$2,883 Zita Peach to succeed Patrick Davies as Board Chair 12 Nov 2026 9:41AM $23.960 $22.740 fallen by 5.09%
$2,883 Q3 2026 DAYBUE net sales up 39%, full year guidance upgraded 5 Nov 2026 9:57AM $19.780 $22.740 risen by 14.96%
$2,883 FDA grants Orphan Drug Designation for NNZ-2591 to treat HIE 2 Nov 2026 10:37AM $20.290 $22.740 risen by 12.07%
$2,883 Trofinetide US patent protections extended to March 2041 29 Sep 2026 10:34AM $19.800 $22.740 risen by 14.85%
$2,883 Pause in Trading 29 Sep 2026 9:59AM $19.820 $22.740 risen by 14.73%
$2,883 Update - Dividend/Distribution - NEU 18 Sep 2026 4:12PM $20.680 $22.740 risen by 9.96%
$2,883 Corporate Presentation, 2 September 2026 2 Sep 2026 8:50AM $19.890 $22.740 risen by 14.33%
$2,883 Dividend/Distribution - NEU 26 Aug 2026 4:56PM $20.150 $22.740 risen by 12.85%
$2,883 Investor presentation, 26 August 2026 26 Aug 2026 10:40AM $22.370 $22.740 risen by 1.65%
$2,883 Growing royalty anchors Neuren first ever dividend program 26 Aug 2026 9:47AM $22.530 $22.740 risen by 0.93%
$2,883 Half Yearly Report and Accounts 26 Aug 2026 9:25AM $22.530 $22.740 risen by 0.93%
$2,883 European Commission grants marketing authorisation for DAYBU 25 Aug 2026 8:31AM $22.450 $22.740 risen by 1.29%
$2,883 Neuren H1 2026 Financial Results Webinar on 26 August 2026 21 Aug 2026 3:19PM $22.420 $22.740 risen by 1.43%
$2,883 Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded 5 Aug 2026 9:52AM $18.610 $22.740 risen by 22.19%
$2,883 Neuren highlights participation in PMSF Family Conference 24 Jul 2026 9:57AM $16.460 $22.740 risen by 38.15%
$2,883 DAYBU recommended for approval in the European Union 29 Jun 2026 7:43AM $12.200 $22.740 risen by 86.39%
$2,883 Application for quotation of securities - NEU 18 Jun 2026 4:49PM $13.250 $22.740 risen by 71.62%
$2,883 Notification of cessation of securities - NEU 1 Jun 2026 5:47PM $14.210 $22.740 risen by 60.03%
$2,883 Notification regarding unquoted securities - NEU 1 Jun 2026 5:40PM $14.210 $22.740 risen by 60.03%
$2,883 Results of Meeting 27 May 2026 4:00PM $13.810 $22.740 risen by 64.66%
$2,883 AGM Chair Address & CEO Presentation 27 May 2026 1:22PM $14.410 $22.740 risen by 57.81%
$2,883 Update - Notification of buy-back - NEU 14 May 2026 7:30AM $12.710 $22.740 risen by 78.91%

1 - 25 of 839 results

Page 1 of 34

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.